Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 4/20 | 0.33 |
| ▸ | HTR7 | P34969 | 4/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD5 | P21918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20325412 | 0.91 | HRH4 (0.36) | HRH3DRD2DRD3HTR1AHTR7 | |
| SCHEMBL21664554 | 0.86 | HRH3 (0.35) | HRH3DRD2DRD3HTR1AHTR7 | |
| SCHEMBL23664600 | 0.78 | RET (0.35) | HRH3DRD2DRD3RET | |
| SCHEMBL19959012 | 0.77 | HRH3 (0.46) | HRH3DRD2DRD3RETDRD1 | |
| SCHEMBL20330273 | 0.74 | HRH3 (0.34) | HRH3RET | |
| SCHEMBL21934596 | 0.73 | HRH3 (0.46) | HRH3DRD2DRD3RETDRD1 | |
| SCHEMBL20235058 | 0.71 | HRH3 (0.36) | HRH3DRD2DRD3HTR1AHTR7 | |
| SCHEMBL20234229 | 0.71 | RET (0.34) | HRH3RET | |
| SCHEMBL18591812 | 0.69 | KCNH2 (0.38) | HRH3DRD2HTR1AHTR7 | |
| SCHEMBL14868545 | 0.68 | GAA (0.50) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | HRH3 3459/4885DRD2 4440/4885DRD3 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.